Skip to main content
峆一药业 logo

峆一药业 — Investor Relations & Filings

Ticker · 920478 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2023-04-13 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920478

About 峆一药业

http://www.heryipharma.com/

Anhui Heyi Pharmaceutical Co., Ltd. specializes in the research, development, production, and sales of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company focuses on providing high-quality chemical products for various therapeutic areas, including cardiovascular, central nervous system, and anti-infective treatments. With a strong emphasis on technological innovation and quality control, it operates advanced manufacturing facilities that adhere to international standards. Its product portfolio includes key intermediates for widely used medications, supporting both domestic and global pharmaceutical supply chains. The company leverages its expertise in complex chemical synthesis to offer customized solutions and reliable supply to its partners in the life sciences sector.

Recent filings

Filing Released Lang Actions
拟续聘会计师事务所公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the company's intention to reappoint an accounting firm (audit firm) for the 2023 fiscal year. It details the background, qualifications, and independence of the accounting firm, the board's approval, and the audit committee's review. It does not contain any actual audit report or financial statements, but rather is a notice about the audit firm appointment process. This fits the category of Audit Report / Information (AR), which includes standalone audit-related announcements and information about audit firms, excluding full annual reports. The document length is short and it is not a report publication announcement or certification. Therefore, the classification is AR with high confidence. FY 2023
2023-04-13 Chinese
国元证券股份有限公司关于安徽峆一药业股份有限公司调整募集资金投资项目拟投入募集资金金额的核查意见
Capital/Financing Update Classification · 95% confidence The document is a verification opinion from the sponsor (Guoyuan Securities) regarding the adjustment of the amount of raised funds to be invested in projects by Anhui Xuyi Pharmaceutical Co., Ltd. It details the fundraising amount, issuance details, approvals by the board and supervisory committee, and compliance with regulatory requirements. The document is not a full financial report but rather a formal verification and opinion on the adjustment of investment amounts of raised funds. It does not contain financial statements or comprehensive financial data. It is a regulatory compliance and verification document related to capital raising and fund usage. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2023-04-13 Chinese
关于治理专项自查及规范活动相关情况的报告
Governance Information Classification · 95% confidence The document is a detailed report on corporate governance self-inspection and compliance activities by Anhui Xuyi Pharmaceutical Co., Ltd. It includes information on company structure, internal systems, board and management composition, decision-making processes, governance constraints, and other compliance matters. The content focuses on governance practices, board and committee structures, and regulatory compliance rather than financial results or audit opinions. There is no indication that this is an annual report, audit report, earnings release, or any other financial report. The document is a governance-related report, detailing internal rules, board structure, and governance practices. Therefore, it fits best under the category 'Governance Information' (CGR). The document length (5150 characters) and detailed content support this classification with high confidence.
2023-04-13 Chinese
国元证券股份有限公司关于安徽峆一药业股份有限公司使用闲置募集资金购买理财产品的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from the sponsor institution (Guoyuan Securities Co., Ltd.) regarding the use of idle raised funds by Anhui Xuyi Pharmaceutical Co., Ltd. to purchase financial products. It includes specifics about the fundraising, usage, investment decisions, risk control, and compliance with regulatory requirements. The document is not a full financial report but rather a regulatory compliance and verification statement related to the use of raised funds. It does not contain financial statements or quarterly/yearly financial results. It is a regulatory filing related to compliance and fund usage verification under securities regulations. The document length is under 5,000 characters and is a formal opinion/report from the sponsor institution, fitting the category of Regulatory Filings (RNS) rather than a full Annual Report, Interim Report, or Capital/Financing Update.
2023-04-13 Chinese
使用闲置募集资金购买理财产品公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the use of idle raised funds by Anhui Xuyi Pharmaceutical Co., Ltd. to purchase financial products. It details the fundraising amount, usage status, investment decision, risk control measures, and includes opinions from independent directors, the supervisory board, and the sponsoring institution. The document does not contain financial statements or comprehensive financial data but is a disclosure about the company's capital management activities related to raised funds. This fits the category of Capital/Financing Update (CAP), as it updates on the company's fundraising usage and capital management activities.
2023-04-13 Chinese
独立董事关于第四届董事会第九次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on various agenda items to be submitted to the shareholders' meeting, including the 2022 annual report, financial statements, audit firm appointment, related party transactions, profit distribution plan, internal control report, capital changes, and remuneration plans. It is a formal announcement expressing independent directors' approval and opinions on these matters, intended for shareholder consideration. The document is relatively short (3098 characters) and does not contain the full annual report or detailed financial statements itself, but rather opinions on those reports and proposals. This fits the profile of a Regulatory Filing (RNS) as it is an official announcement related to governance and regulatory compliance but not the full report or a direct financial report. It is not a full Annual Report (10-K), nor a Management Report or Remuneration Information report, but an independent directors' statement on agenda items for a shareholders meeting.
2023-04-13 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.